Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
38.57
USD
|
+0.29%
|
|
-0.18%
|
+4.36%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,591
|
5,765
|
5,659
|
7,694
|
4,882
|
4,900
|
-
|
-
|
Enterprise Value (EV)
1 |
2,874
|
6,014
|
5,794
|
8,837
|
6,046
|
5,901
|
5,322
|
5,177
|
P/E ratio
|
-35.5
x
|
46.9
x
|
14.7
x
|
39.5
x
|
17.6
x
|
12.8
x
|
9.46
x
|
7.17
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
13.2
x
|
21.5
x
|
12.8
x
|
11.7
x
|
5.89
x
|
5.13
x
|
4.45
x
|
3.73
x
|
EV / Revenue
|
14.7
x
|
22.5
x
|
13.1
x
|
13.4
x
|
7.29
x
|
6.18
x
|
4.84
x
|
3.94
x
|
EV / EBITDA
|
-45.2
x
|
40.8
x
|
20.8
x
|
28.1
x
|
14.2
x
|
10.8
x
|
7.94
x
|
6.23
x
|
EV / FCF
|
-32.1
x
|
114
x
|
19.4
x
|
37.6
x
|
-
|
12.5
x
|
8.8
x
|
7.02
x
|
FCF Yield
|
-3.11%
|
0.88%
|
5.14%
|
2.66%
|
-
|
8.03%
|
11.4%
|
14.3%
|
Price to Book
|
26.4
x
|
38.2
x
|
28.1
x
|
45.3
x
|
-
|
8.66
x
|
4.89
x
|
3.87
x
|
Nbr of stocks (in thousands)
|
146,142
|
134,972
|
140,725
|
135,213
|
132,098
|
127,054
|
-
|
-
|
Reference price
2 |
17.73
|
42.71
|
40.21
|
56.90
|
36.96
|
38.57
|
38.57
|
38.57
|
Announcement Date
|
2/24/20
|
2/23/21
|
2/22/22
|
2/21/23
|
2/20/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
196
|
267.6
|
443.3
|
660.1
|
829.3
|
954.4
|
1,100
|
1,312
|
EBITDA
1 |
-63.54
|
147.5
|
278.9
|
315
|
426.2
|
544.1
|
670.1
|
831.1
|
EBIT
1 |
-67.61
|
144.3
|
275.9
|
267.5
|
337.6
|
474.9
|
619.5
|
820.5
|
Operating Margin
|
-34.5%
|
53.91%
|
62.24%
|
40.53%
|
40.71%
|
49.75%
|
56.31%
|
62.52%
|
Earnings before Tax (EBT)
1 |
-72.25
|
129.3
|
248.5
|
248.9
|
348.3
|
472.4
|
624
|
822.6
|
Net income
1 |
-72.24
|
129.1
|
402.7
|
202.1
|
281.6
|
369.7
|
483.7
|
628.5
|
Net margin
|
-36.86%
|
48.24%
|
90.84%
|
30.62%
|
33.96%
|
38.74%
|
43.97%
|
47.89%
|
EPS
2 |
-0.5000
|
0.9100
|
2.740
|
1.440
|
2.100
|
3.017
|
4.077
|
5.382
|
Free Cash Flow
1 |
-89.46
|
52.95
|
298
|
235.3
|
-
|
474
|
604.5
|
738
|
FCF margin
|
-45.65%
|
19.79%
|
67.22%
|
35.65%
|
-
|
49.66%
|
54.95%
|
56.23%
|
FCF Conversion (EBITDA)
|
-
|
35.89%
|
106.84%
|
74.7%
|
-
|
87.12%
|
90.2%
|
88.8%
|
FCF Conversion (Net income)
|
-
|
41.02%
|
73.99%
|
116.41%
|
-
|
128.2%
|
124.97%
|
117.41%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/20
|
2/23/21
|
2/22/22
|
2/21/23
|
2/20/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
115.8
|
102
|
117.3
|
152.4
|
209
|
181.5
|
162.1
|
221
|
216
|
230
|
200.8
|
208
|
253.1
|
291.7
|
242.7
|
EBITDA
1 |
81.74
|
57.31
|
81.19
|
40.84
|
85.3
|
79.45
|
74.54
|
115.1
|
114.9
|
121.7
|
116.2
|
111.6
|
144.3
|
189.8
|
-
|
EBIT
1 |
75.59
|
56.53
|
75.67
|
34.06
|
83.29
|
74.51
|
53.8
|
94.46
|
88.28
|
101
|
90.76
|
94.11
|
135.3
|
155.4
|
144.8
|
Operating Margin
|
65.26%
|
55.42%
|
64.52%
|
22.35%
|
39.86%
|
41.05%
|
33.18%
|
42.73%
|
40.86%
|
43.92%
|
45.2%
|
45.24%
|
53.48%
|
53.28%
|
59.66%
|
Earnings before Tax (EBT)
1 |
74.11
|
54.81
|
74.41
|
30.01
|
73.71
|
70.79
|
52.24
|
93.16
|
101.8
|
101.2
|
93.3
|
92.83
|
132.8
|
154.6
|
141.3
|
Net income
1 |
216.6
|
66.77
|
60.11
|
22.68
|
61.63
|
57.7
|
39.62
|
74.75
|
81.84
|
85.39
|
72.01
|
71.75
|
105.7
|
125.6
|
113
|
Net margin
|
186.99%
|
65.46%
|
51.25%
|
14.89%
|
29.49%
|
31.79%
|
24.43%
|
33.82%
|
37.88%
|
37.12%
|
35.86%
|
34.49%
|
41.75%
|
43.05%
|
46.57%
|
EPS
2 |
1.480
|
0.4600
|
0.4300
|
0.1600
|
0.4400
|
0.4200
|
0.2900
|
0.5700
|
0.6100
|
0.6500
|
0.5867
|
0.6117
|
0.8567
|
0.9867
|
0.9400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/2/21
|
2/22/22
|
5/10/22
|
8/9/22
|
11/8/22
|
2/21/23
|
5/9/23
|
8/8/23
|
11/6/23
|
2/20/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
282
|
250
|
136
|
1,143
|
1,163
|
1,001
|
422
|
277
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-4.444
x
|
1.691
x
|
0.4867
x
|
3.63
x
|
2.729
x
|
1.84
x
|
0.6296
x
|
0.333
x
|
Free Cash Flow
1 |
-89.5
|
53
|
298
|
235
|
-
|
474
|
605
|
738
|
ROE (net income / shareholders' equity)
|
-42.4%
|
106%
|
169%
|
110%
|
293%
|
169%
|
91.7%
|
82.5%
|
ROA (Net income/ Total Assets)
|
-14.4%
|
22.5%
|
34.9%
|
13.7%
|
20.8%
|
26.7%
|
28.8%
|
29.6%
|
Assets
1 |
503.1
|
572.9
|
1,153
|
1,473
|
1,354
|
1,387
|
1,678
|
2,124
|
Book Value Per Share
2 |
0.6700
|
1.120
|
1.430
|
1.260
|
-
|
4.450
|
7.890
|
9.960
|
Cash Flow per Share
2 |
-
|
0.3900
|
2.040
|
1.710
|
-
|
3.750
|
-
|
-
|
Capex
1 |
4.04
|
2.5
|
1.46
|
4.81
|
-
|
2
|
2
|
12
|
Capex / Sales
|
2.06%
|
0.94%
|
0.33%
|
0.73%
|
-
|
0.21%
|
0.18%
|
0.91%
|
Announcement Date
|
2/24/20
|
2/23/21
|
2/22/22
|
2/21/23
|
2/20/24
|
-
|
-
|
-
|
Last Close Price
38.57
USD Average target price
50.5
USD Spread / Average Target +30.93% Consensus |
1st Jan change
|
Capi.
|
---|
| +4.36% | 4.9B | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|